Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Patent
1994-07-11
1999-09-28
Stanton, Brian R.
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
514 44, C12N 1563, A61K 4800
Patent
active
059584033
ABSTRACT:
Disclosed is a method of localized immunosuppression which may be used for preventing graft rejection or for preventing tissue destruction due to autoimmune disease. Also disclosed is a protein suppressor factor that is secreted by cloned anergic T-cells, blocks interleukin 2 (IL-2) stimulated T-cell proliferation, has an apparent molecular weight of between 10 and 30 kilodaltons, can be inactivated by heating to 65.degree. C. for 15 minute, blocks interleukin 4 (IL-4) stimulated T-cell proliferation in vitro, is non-cytotoxic to T-cells, and does not inhibit the production of IL-2 by T-cells in vitro.
REFERENCES:
patent: 4675285 (1987-06-01), Clark et al.
patent: 5171841 (1992-12-01), Laurence
Aruffo, A., et al., Molecular cloning of a CD28 CDNA by a high-efficiency COS cell expression system, PNAS 84:8573-7, 1987.
Blackman, M.A., et al., A role for clonal inactivation in T-cell tolerance to Mls-1a, Nature 345:540, 1990.
Boitard, C., et al., T-cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice, J. Exp. Med. 169:1669, 1989.
Bottazzo, G.F., et al., In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis, N. Eng. J. Med. 313:353, 1985.
Burkly, L.C., et al., T-cell tolerance by clonal energy in transgenic mice with nonlymphoid expression of MHC class II I-E, Nature 342:564, 1989.
Burkly, L.C., et al., Tolerance in transgenic mice expressing major histocompatibility molecules extrathymically on pancreatic cells, Science 248:1364, 1990.
Charlton, B., et al., Cyclophosphamide-induced diabetes in NOD/WEHI mice. Evidence for suppression in spontaneous autoimmune diabetes mellitus, Diabetologia 38:441, 1989.
Chiu, C-P., et al., Multiple biological activities are expressed by a mouse interleukin 6 cDNA clone isolated from bone marrow stromal cells, PNAS 85:7099, 1988.
Danielpour, D., et al., Immunodetection and quantitation of the two forms of transforming growth factor-beta (TGF-beta 1 and TGF-beta 2) secreted by cells in culture, J. Cel. Physiol. 138:79, 1989.
Derynck, R., et al., The murine transforming growth factor-.beta. precursor, J. Biol. Chem. 261:4377, 1986.
Fink, P.J., et al., Veto cells, Ann. Rev. Imunol. 6:115, 1988.
Fransen, L., et al., Molecular cloning of mouse tumor necrosis factor cDNA and its eukaryotic expression, Nucl. Ac. Res. 13:4417, 1985.
Gillis, S., et al., Long term culture of tumour specific cytotoxic T-cells, Nature 268:154, 1977.
Gray, P.W., et al., Cloning and expression of murine immune interferon cDNA, PNAS 80:5842, 1983.
Kaplan, G., et al., Rational immunotherapy with interleukin 2, Bio/Tech. 10:157-62, 1982.
Bromberg, Current Opinion in Immunology, 7:639-643, 1995.
Morris, Cell Transplantation, 2:7-12, 1993.
Chavin et al., Surgical Forum, 44(0):407-409, 1993.
Tahara et al., Transplantation Proceedings, 24(6):2975-2976, Dec. 1992.
Libermann et al., J. American Society of Nephrology, 6(3):1059, abstract 333, Sep. 1995.
Spits et al., Int. Arch. Allergy Immunol., 99:8-15, 1992.
Antin et al., Blood, 80(12):2964-2968, Dec. 15, 1992.
Diaz-Gallo et al., J. American Society of Nephrology, 3(3):583, abstract 82P, Sep. 1992.
Kelley et al., Blood Purification, 13:199-205, 1995.
Ricordi et al., Clinical Transplantation, 7:75-81, 1993.
Broadley et al., FASEB J., 5(4):A539, 1991.
Kappler, J.W., et al., T-cell tolerance by clonal elimination in the thymus, Cell 49:273, 1987.
Kashima, N., et al., Unique structure of murine interleukin-2 as deduced from cloned cDNAs, Nature 313:402, 1985.
Lee, F., et al., Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell-and mast-cell-stimulating activities, PNAS 83:2061, 1986.
Makino, S. et al., Breeding of a non-obese, diabetic strain of mice, Exp. Anim. 29:1, 1980.
Miyazaki, A., et al., Predominance of T Lymphocytes in pancreatic islets of spleen of pre-diabetic non-obese diabetic (NOD) mice: a longitudinal study, Clin. Exp. Immunol. 60:622, 1985.
Mueller, D.L., et al., Clonal expansion versus functional clonal inactivation. A costimulatory signalling pathway determines the outcome of T-cell antigen receptor occupancy, Ann. Rev. Immunol 7:445, 1989.
Murray, L.J., et al., In vivo cytokine gene expression in T-cell subsets of the autoimmune MRL/MP-lpr/lpr mouse, Eur. J. Immunol. 20:163, 1990.
Ortaldo, J.R., et al., Mechanistic studies of transforming growth factor-B inhibition of IL-2 dependent activation of CD3-large granular lymphocyte functions, J. Immunol. 146:3791, 1991.
Pankewycz, O., et al., Islet-infiltrating T-cell clones from non-obese diabetic mice that promote or prevent accelerated onset of diabetes, Eur. J. Immunol. 21:873, 1991.
Ruegemer, J.J., et al., Regulatory effects of transforming growth factor-B on IL-2 and IL-4 dependent cell cycle progression, J. Immunol. 144:1767, 1990.
Russell, J.H., et al., Receptor-stimulated death pathway is opened by antigen in mature T-cells, Proc. Natl. Acad. Sci. USA 88:2151, 1991.
Webb, S., et al., Extrathymic tolerance of mature T-cells: Clonal elimination as a consequence of immunity Cell, 63:1249, 1990.
Wicker, L.S., et al., Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice, Diabetes 35:855, 1986.
Schwyzer et al., Partial Purification and Biochemical Characterization of AT Cell Suppressor Factor Produced by Human Glioblastoma Cells, J. Immun. 134(2):1003-1009, 1985.
Kuppner et al., The Glioblastoma-Derived T-Cell Suppressor Factor/Transforming Growth Factor Beta.sub.2 Inhibits the Generation of Lymphokine-Activated Killer (LAK) Cells, Int. J. Cancer 42:562-567 1988.
Colizzi et al., Suppressor cells induced by BCG release non-specific factors in vitro which inhibit DNA DNA synthesis and interleukin-2 production, J. Immun. 51:65-71, 1984.
Almawi et al., Induction of Suppression by a Murine Nonspecific Suppressor-Inducer Cell Line (M1-A5). III. Partial Purification of the Suppressor Cell-Inducing Factors, J. Mol. Cell Immunol. 3:156-166, 1987.
Redondo et al., Inhibition of interleukin 2-induced proliferation of cloned murine T cells by Glucocorticoids Possible involvement of an inhibitory protein, Eur. J. Immunol. 18:1555-1559, 1988.
Fidel et al., Regulation of Granulomatous Inflammation in Murine Schistosomiasis, J. of Immunol. 146:1941-1948, 1991.
Mosman, Current Protocols in Immunology, 1:6.14.1-6.14.8, 1991.
Gotoh et al., "Brief Communications", Transplantation 40:437-438.
Fiorentino et al., "IL-10 Inhibits Cytokine Production by Activated Macroophages", The American Association of Immunologists, 147(11):3815-3822, 1991.
Bloom, J. Clinical Investigation 91:1265-1266, 1993.
Diat-Gallo, PNAS 89:8566-8660, 1991.
Business Newsweek, Issued May 28, 1990, "The Genetic Age", pp. 68-83.
Libermann Towia
Strom Terry
Beth Israel Hospital Association
Hauda Karen M.
Stanton Brian R.
LandOfFree
Methods and compounds for prevention of graft rejection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compounds for prevention of graft rejection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compounds for prevention of graft rejection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-700097